Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 –
Stay updated with breaking news from Tom Riga. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 –
Operator: Good morning, and welcome to the Assertio Holdings Inc Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in -a listen-only mode.
-- Q1 2023 net sales of $15.6 million, an increase of 54% compared to Q4 2022 -- -- Company to be acquired by Assertio Holdings, Inc., delivering value to stakeholders in an all stock and... | May 9, 2023
Assertio Holdings and Spectrum Pharmaceuticals Transaction April 25, 2023 Corporate Speakers · ... | April 25, 2023
Spectrum Pharmaceuticals is a commercial-stage biopharmaceutical company focused on novel and targeted oncology.